Sight Sciences (NASDAQ:SGHT – Get Free Report) and Surmodics (NASDAQ:SRDX – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, dividends, valuation, institutional ownership and profitability.
Profitability
This table compares Sight Sciences and Surmodics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Sight Sciences | -65.90% | -45.68% | -32.27% |
| Surmodics | -1.16% | 3.88% | 2.59% |
Valuation and Earnings
This table compares Sight Sciences and Surmodics’ gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Sight Sciences | $79.40 million | 3.74 | -$55.55 million | ($1.12) | -5.32 |
| Surmodics | $120.82 million | 4.85 | -$1.54 million | $0.95 | 43.26 |
Volatility and Risk
Sight Sciences has a beta of 2.75, indicating that its share price is 175% more volatile than the S&P 500. Comparatively, Surmodics has a beta of 1.18, indicating that its share price is 18% more volatile than the S&P 500.
Insider and Institutional Ownership
55.5% of Sight Sciences shares are held by institutional investors. Comparatively, 96.6% of Surmodics shares are held by institutional investors. 28.9% of Sight Sciences shares are held by insiders. Comparatively, 8.9% of Surmodics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Analyst Recommendations
This is a summary of recent ratings and recommmendations for Sight Sciences and Surmodics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Sight Sciences | 1 | 5 | 1 | 0 | 2.00 |
| Surmodics | 0 | 4 | 0 | 0 | 2.00 |
Sight Sciences presently has a consensus price target of $5.70, suggesting a potential downside of 4.36%. Surmodics has a consensus price target of $50.00, suggesting a potential upside of 21.65%. Given Surmodics’ higher probable upside, analysts clearly believe Surmodics is more favorable than Sight Sciences.
Summary
Surmodics beats Sight Sciences on 10 of the 13 factors compared between the two stocks.
About Sight Sciences
Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. It also offers TearCare System, a wearable eyelid technology for adult patients with evaporative dry eye disease due to meibomian gland dysfunction, as well as related components. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. Sight Sciences, Inc. was incorporated in 2010 and is headquartered in Menlo Park, California.
About Surmodics
Surmodics, Inc., together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device for neurovascular, peripheral, coronary, and structural heart, and other markets, as well as manufacturing of vascular intervention medical devices, including drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths. The IVD segment develops, manufactures, and sells chemical and biological components for in vitro diagnostic immunoassay and molecular tests, as well as diagnostic and biomedical research markets. This segment offers protein stabilizers, substrates, surface coatings, and antigens. The company was founded in 1979 and is headquartered in Eden Prairie, Minnesota.
Receive News & Ratings for Sight Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sight Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
